Medical and scientific researches in the last few years have become increasingly global, cross-national, cross-cultural, and collaborative. Today, one fifth of the medical and scientific papers have international coauthors. This reality is a reflection of globalization of modern day life and easy communications and movement of health professionals and patients. International collaboration is emerging as a norm and is an accepted form of current research environment. It is strongly encouraged by funding agencies.

The sheer volume of international collaborations has been increased substantially during the last 20 years.[1-2] This increase is also noticed in the number of internationally co-authored papers between the developed (usually referred to in political jargon as the ‘North’) and developing and emerging countries (usually referred to as the ‘South’, for example, India and Bangladesh, Mexico and Brazil, China and Pakistan). Despite its late start, China has published many collaborative papers with most Asian countries and also with the North, confirming the effectiveness of China’s current open-door policy. Papers resulting from international collaboration appear in high-impact journals and are cited more often than papers that are the outcome of local research.[3] Chen et al.,[3] reported that only 7.4% of the papers appearing in journals with an impact factor equal to or greater than 5 were published by the local authors during the study period in Taiwan (1990-2004) compared to 13.6% of the publications that had international collaboration. Taiwan’s researchers collaborated with 76 countries, with the greatest share from USA (69.9%). Although the majority of collaborations are mainly between the North and the South, only one fifth are South-South collaborations (collaboration between developing countries).[4]

However, majority of these collaborations are still disorganized efforts, and they vary according to the centers and universities they are originating from. There are no coherent international collaborations, and many failures have been reported. We can summarize the patterns of collaboration as follows:

1. Short-term project-oriented collaboration, where a few centers in different countries are working together for one project. This is often controlled by the availability and the policy of funding agencies.

2. Long-term collaboration, forming an ‘alliance’ between research organizations who share the same interest. There are no rules to govern these activities, which are carried out on an ad hoc basis. It is most likely to happen amongst people who have trained in the same center or are sharing the same interest.

3. Organized international collaboration, which is usually initiated by centers of excellence trying to find new research (and may be commercial) opportunities in a promising emerging market. We are seeing an increase in this form of collaboration, where centers of excellence in the developed countries are opening research offices to facilitate and enhance continuous collaborations. These centers are targeting opportunities in many developing countries such as the Middle East, China, and Southeast Asia.

4. The large, learned scientific societies are now an accepted platform of international collaborations. American Thoracic Society is an example. It attracts delegates from all over the world, and it has become more international than ‘American.’ The 2007 American Thoracic Society conference in San Francisco was attended by over 16,000 people from 90 countries. Unfortunately, most of the sponsorship and attendance is governed by commercial interest of the pharmaceutical companies rather than scientific motivation and need. There is also a trend emerging whereby these regional societies are forging a very close scientific collaboration with each other, for example, the close association of American Thoracic Society and European Respiratory Society, which results in many combined guidelines and expert documents. Many such collaborations are present in the genetic field of infectious diseases,[5] but most are in infant stages and need further support and funding.

5. International cross-border activities such as the Global Alliance Against Chronic Respiratory Diseases (GARD) http://www.who.int/respiratory/gard/en/; and Global...
6. A growing interest towards conducting clinical trials and involving developing countries, where commercial organizations, in particular, pharmaceutical companies, are becoming increasingly active in this field.

7. There is an increasing trend of establishing an equal partnership with scientists from both the North and the South. For example, we have noticed the need to collaborate in 'pulmonary vascular disease' on a global scale. This condition started to attract attention, and more patients were diagnosed as therapies started to be available. Although the condition may affect less than 150,000 people in the west, it is far more common in the developing world (with an estimate of more than 25 million people) because of the other etiological factors which are not seen in the western environment. Unfortunately, the commercial power in marketing drugs has helped in shaping the condition to the extent that it only reflects the interest of a few in the North and hinders progress of the many. This situation prompted the formation of a virtual institute for pulmonary vascular diseases, (www.pvri.info), which includes equal partnership of experts and researchers from the North and the South.

8. Collaboration as a result of the growing global health threats, including climate changes, AIDS, tuberculosis, malaria, chronic obstructive lung diseases, and the easy spread of these conditions, as we have seen recently with avian flu. This makes the collaboration between nations for research and exchange of knowledge and information not only a luxury but a necessity.

International Research Corporation has always helped scientists to keep abreast of international science and share expertise and resources which enhance the scientific community and in-house training. It benefits both the health care system and the population as it may provide new treatments and may be introduced to ensure investment in a research capacity, particularly infrastructure research capacity such as research nurses and research associates. Mechanisms must be introduced to ensure investment in a research capacity, particularly infrastructure research capacity such as research nurses and research associates. Indeed, current funding, averaging around US$ 20,000, is too low even to ensure that a single country’s research is successful. Although there are increasing funding opportunities, mainly via philanthropic organizations, some NGOs, and even governmental organizations, the sheer problem is so huge that more is continually needed.

Funding is a big issue which needs to be considered seriously considering that more than 90% of the world’s ‘potential years of life lost (PYLL)’ belong to the developing world, but it attacks less than 10% of global research funds. Indeed, many countries have built up experience in the development, appraisal, and implementation of guidelines, there has been no established forum for collaboration at an international level. In an effort to partly resolve this issue, in 2002 the international Guidelines International Network (GIN) was formed. This network aimed at promoting systematic guideline development and implementation which ‘seeks to improve the quality of health care by promoting systematic development of clinical practice guidelines.’ There are also other similar organizations aiming to develop, teach, and promote evidence-based health care and provide support and resources to anyone who wants to make use of these, such as Oxford Centre for Evidence-based Medicine. Funding is a big issue which needs to be considered seriously considering that more than 90% of the world’s ‘potential years of life lost (PYLL)’ belong to the developing world, but it attacks less than 10% of global research funds. Indeed, current funding, averaging around US$ 20,000, is too low even to ensure that a single country’s research is successful. Although there are increasing funding opportunities, mainly via philanthropic organizations, some NGOs, and even governmental organizations, the sheer problem is so huge that more is continually needed.

While minimum research capacity may exist in many developing countries, the fact that lead institutions, as well as study countries, are concentrated in a handful of centers attests to great disparities in research capacity. Mechanisms must be introduced to ensure investment in a research capacity, particularly infrastructure research capacity such as research nurses and research associates. Careful consideration of the cultural, social, and intellectual properties of the developing countries has played a part in maintaining a successful research partnership. Patenting
of biological materials, including plants, animals, and even discoveries, made in the developing countries, whether due to existing knowledge of the local and indigenous people or by considerable input from local researchers, is becoming a key issue of contention between multinational companies and health care campaigners and other campaigners (usually referred to by the negative term biopiracy).[17] As a general rule, the sponsoring agency should agree in advance of the research that any product developed through such research will be made reasonably available to the inhabitants of the host community or country at the completion of the research. The potential for clinical research to exploit populations has raised much concern recently. It is advisable that collaborators must enter into partnership, which means that researchers must engage the population in development and evaluation of, and benefiting from the researches.[18,19] Lastly, the developing country must be empowered to participate in debate and decision making about priority setting for research collaboration. A good starting point for this is for countries in a specific region to start to collaborate to tackle common regional health problems.[19]

In conclusion, research collaboration is an enormous and powerful tool which provides mutual benefits to all parties. It needs careful planning and considerable thought to the diversity of the human society. The North-South collaboration can be strengthened by promoting further involvement of countries such as Germany, France, Belgium, and Spain in funding, supporting, and leading research in developing countries.

References

1. Smey JC, Trondal J. Globalisation or Europeanisation? International contact among university staff. Higher Educ 2005;49:449-66.
2. Chen TJ, Chen YC, Hwang SJ, Chou LF. International collaboration of clinical medicine research in Taiwan, 1990-2004: A bibliometric analysis. J Chin Med Assoc 2007;70:110-6.
3. Arunachalam S, Srinivasan R, Raman V. International collaboration in science: Participation by the Asian giants. Scientometrics 1994;30:7-22.
4. Block M. The state of international collaboration for health systems research: What do publications tell? Health Res Policy Syst 2006;4:7.
5. Ross K. Tracking the spread of infectious disease: Two networks prove the power of international collaboration. EMBO Rep 2006;7:855.
6. KFPE, Enhancing research capacity in D, transition C. Experience, discussions, strategies and tools for building research capacity and strengthening institutions in view of promoting research for sustainable development. Geographica Bernensia: Berne; 2001.
7. Mari JJ, Lozano JM, Duley L. Erasing the global divide in health research. BMJ 1997;314:390.
8. Johnstone P, McConnan I. Primary health care led NHS learning from developing countries. BMJ 1995;311:891-2.
9. Varmus H, Satcher D. Ethical complexities of conducting research in developing countries. N Engl J Med 1997;337:1003-5.
10. Tan-Torres Edejer T. North-South research partnerships: The ethics of carrying out research in developing countries. BMJ 1999;319:438-41.
11. SDC. Research policy of the Swiss Agency for Development Cooperation (SDC). Berne: SDC; 2002.
12. CIOMS. International Ethical Guidelines for Biomedical Research Involving Human Subjects. Available from: http://www.cioms.ch/frame_guidelines_nov_2002.htm.
13. Bui TD, Markte WH. The Global Burden of Disease. Understanding Global Health. 2007.
14. CHRD. Commission on Health Research for Development, Health research. Essential link to equity in development. Oxford University Press; 1990. p. 136.
15. ChitrSitthi-amorn C, Somrongthong R. Alliance for health policy and systems research, strengthening health systems: The role and promise of health policy and systems research Strengthening health research capacity in developing countries: A critical element for achieving health equity. Geneva: Alliance HPSR; 2004. p. 813-7.
16. Anderson G, Metcalfe A. Calling for international collaborative research in nursing, genetics and genomics: A discussion paper. Int J Nurs Stud 2008;45:323-8.
17. McKee M, Gilmore AB, Schwabe N. International cooperation and health, Part I: Issues and concepts. Br Med J 2005;335:628.
18. Hwang K. International collaboration in multilayered center-periphery in the globalization of science and technology. Sci Technol Hum Values 2008;33:101-33.
19. Swingler GH, Pillay V, Pienaar ED, Ioannidis JP. International collaboration, funding and association with burden of disease in randomized controlled trials in Africa. Bull World Health Organ 2005;83:511-7.

Source of Support: Nil, Conflict of Interest: None declared.

Announcement

The editorial board of Annals of Thoracic Medicine is pleased to announce that the journal is now indexed with a number of international bibliographic databases including:
1. Citation Index Expanded (also known as SciSearch®)
2. Journal Citation Reports/Science Edition
3. Web of Science
4. EMBASE
5. CAB Abstracts, Global Health
6. CINAHL